Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline
暂无分享,去创建一个
E. Perry | I. McKeith | C. Holmes | C. Ballard | E. Rowan | E. Jaros | R. Perry | M. Piggott | Clive Holmes | Evelyn Jaros | Margaret A Piggott | Clive G Ballard | Elise Rowan | Ian G McKeith | Robert H Perry | Elaine K Perry
[1] H. Haeske-Dewick. Hallucinations in Parkinson's disease: Characteristics and associated clinical features , 1995 .
[2] Abraham Weizman,et al. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. , 1996, Advances in neurology.
[3] P. Ince,et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies , 1997, Acta neurologica Scandinavica.
[4] G A Chase,et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.
[5] G. Zubenko,et al. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease , 1991, Biological Psychiatry.
[6] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[7] I G McKeith,et al. Report of the second dementia with Lewy body international workshop , 1999, Neurology.
[8] I G McKeith,et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. , 1999, Brain : a journal of neurology.
[9] P. Thompson,et al. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. , 2001, The Journal of clinical psychiatry.
[10] S. Aalto,et al. Extrastriatal dopamine D2 receptors in Parkinson's disease: a longitudinal study , 2003, Journal of Neural Transmission.
[11] E. Perry,et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.
[12] E. Perry,et al. Visual hallucinations are associated with lower αbungarotoxin binding in dementia with Lewy bodies , 2001, Pharmacology Biochemistry and Behavior.
[13] W. Hoefnagels,et al. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine]. , 2003, Nederlands tijdschrift voor geneeskunde.
[14] Robert M. Kessler,et al. Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride , 1993, Brain Research.
[15] V Kaasinen,et al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease , 2000, Neurology.
[16] D. Visvikis,et al. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs , 1999, British Journal of Psychiatry.
[17] K. Marder,et al. The Columbia University Scale for Psychopathology in Alzheimer's disease. , 1992, Archives of neurology.
[18] K. Kosaka,et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.
[19] M. Cookson,et al. Nicotinic receptors in the putamen of patients with dementia with Lewy bodies and Parkinson's disease: relation to changes in α-synuclein expression , 2002, Neuroscience Letters.
[20] E. Perry,et al. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types , 1990, Journal of neural transmission. Parkinson's disease and dementia section.
[21] L. A. Fetsko,et al. Dopamine D2L receptor knockout mice display deficits in positive and negative reinforcing properties of morphine and in avoidance learning , 2002, Neuroscience.
[22] J. Joyce,et al. Dopamine D2 receptor expression in hippocampus and parahippocampal cortex of rat, cat, and human in relation to tyrosine hydroxylase‐immunoreactive fibers , 1994, Hippocampus.
[23] Alan J. Thomas,et al. A comparison of the efficacy of donepezil in Parkinson's disease with Dementia and Dementia with Lewy bodies , 2005, International journal of geriatric psychiatry.
[24] O. Lopez,et al. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. , 1998, Archives of neurology.
[25] E. Perry,et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. , 1999, The American journal of psychiatry.
[26] Murat Emre,et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study , 2000, The Lancet.
[27] S. Tanada,et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. , 2002, Archives of general psychiatry.
[28] A. Myers,et al. Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease , 1998, Brain Research.
[29] K. Erlandsson,et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. , 2003, The American journal of psychiatry.
[30] J. Joyce,et al. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. , 1997, Archives of general psychiatry.
[31] A. Burns,et al. Psychiatric Phenomena in Alzheimer's Disease. I: Disorders of Thought Content , 1990, British Journal of Psychiatry.
[32] J. Meador-Woodruff,et al. Linking the Family of D2 Receptors to Neuronal Circuits in Human Brain: Insights into Schizophrenia , 1997, Neuropsychopharmacology.
[33] P. Hof,et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease , 2003, Acta Neuropathologica.
[34] T. Robbins,et al. Chemical neuromodulation of frontal-executive functions in humans and other animals , 2000, Experimental Brain Research.
[35] E. Perry,et al. Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia , 1990, Journal of neurochemistry.
[36] E. Perry,et al. Cerebral Cholinergic Activity Is Related to the Incidence of Visual Hallucinations in Senile Dementia of Lewy Body Type , 1990 .
[37] S. Leurgans,et al. Age‐related influences on the clinical characteristics of new‐onset hallucinations in Parkinson's disease patients , 2006, Movement disorders : official journal of the Movement Disorder Society.
[38] M. Laakso,et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease , 2003, The European journal of neuroscience.
[39] J. Joyce,et al. Loss of Dopamine D2 Receptors in Alzheimer's Disease with Parkinsonism But Not Parkinson's or Alzheimer's Disease , 1998, Neuropsychopharmacology.
[40] Robert H. Perry,et al. Senile dementia of Lewy body type A clinically and neuropathologically distinct form of Lewy body dementia in the elderly , 1990, Journal of the Neurological Sciences.
[41] Wayne C. Drevets,et al. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type , 1989, Biological Psychiatry.
[42] A. Kurz,et al. DELUSIONS AND HALLUCINATIONS IN ALZHEIMER'S DISEASE: RESULTS FROM A TWO‐YEAR LONGITUDINAL STUDY , 1996 .
[43] D. Blanchard,et al. Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[44] R. Lévy,et al. Psychiatric Phenomena in Alzheimer's Disease. IV: Disorders of Behaviour , 1990, British Journal of Psychiatry.
[45] K. Neve,et al. Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine. , 1992, The Journal of pharmacology and experimental therapeutics.
[46] Patrick R Hof,et al. Mice Lacking Dopamine D2 and D3 Receptors Have Spatial Working Memory Deficits , 2002, The Journal of Neuroscience.
[47] J. Moossy,et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. , 1991, Archives of neurology.
[48] Dag Aarsland,et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. , 2005, The Journal of clinical psychiatry.
[49] L. Nyberg,et al. The correlative triad among aging, dopamine, and cognition: Current status and future prospects , 2006, Neuroscience & Biobehavioral Reviews.
[50] A. Burns,et al. Psychiatric Phenomena in Alzheimer's Disease. III: Disorders of Mood , 1990, British Journal of Psychiatry.
[51] E. Perry,et al. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use , 1998, Neuroscience.
[52] Y. Hirayasu,et al. Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: A case report , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[53] G. Stebbins,et al. Intravenous levodopa in hallucinating Parkinson's disease patients , 1998, Neurology.
[54] S Minoshima,et al. Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.
[55] I. McKeith,et al. Neuroleptic sensitivity to risperidone in Lewy body dementia , 1995, The Lancet.
[56] E. Perry,et al. Nigrostriatal dopaminergic activities in dementia with lewy bodies in relation to neuroleptic sensitivity: comparisons with parkinson’s disease , 1998, Biological Psychiatry.
[57] J. T. Tran,et al. Dementia with lewy bodies: therapeutic opportunities and pitfalls. , 2006, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.
[58] C. Fairburn,et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up , 1997, BMJ.
[59] J. Trojanowski,et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases , 2002, Annals of neurology.
[60] E. Perry,et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies , 2000, Annals of neurology.
[61] Hans Förstl,et al. Psychotic features and the course of Alzheimer's disease: relationship to cognitive, electroencephalographic and computerized tomography findings , 1993, Acta psychiatrica Scandinavica.
[62] G. Wilcock,et al. The prevalence and phenomenology of psychotic symptoms in dementia sufferers , 1995 .
[63] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[64] J. Copeland,et al. Computerized diagnosis from a standardized history schedule: A preliminary communication about the organic section of the HAS–AGECAT system , 1992 .
[65] A. Antal,et al. Dopamine D2 receptor blockade alters the primary and cognitive components of visual evoked potentials in the monkey, Macaca fascicularis , 1997, Neuroscience Letters.
[66] A. Burns,et al. Psychiatric Phenomena in Alzheimer's Disease. II: Disorders of Perception , 1990, British Journal of Psychiatry.
[67] L. Schneider,et al. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. , 1994, Archives of neurology.
[68] S. Papapetropoulos,et al. Factors associated with drug–induced visual hallucinations in Parkinson's disease , 2005, Journal of Neurology.
[69] J. Joyce,et al. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[70] S. Wisniewski,et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. , 2001, Archives of neurology.